Rituximab with prednisolone as first-line treatment in pemphigus vulgaris

M Scorer¹, J F Setterfield^{2

3}, K E Harman¹

Affiliations

¹ University Hospitals Leicester, Leicester Royal Infirmary, Infirmary Square, Leicester, U.K.
² St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, Guy's Campus, Great Maze Pond, London, U.K.
³ Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, U.K.

Comment

M Scorer et al. Br J Dermatol. 2020 May.

. 2020 May;182(5):1078-1079.

doi: 10.1111/bjd.18814. Epub 2020 Jan 20.

M Scorer¹, J F Setterfield^{2

3}, K E Harman¹

¹ University Hospitals Leicester, Leicester Royal Infirmary, Infirmary Square, Leicester, U.K.
² St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, Guy's Campus, Great Maze Pond, London, U.K.
³ Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, U.K.

No abstract available

Comment on

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases. Chen DM, et al. Br J Dermatol. 2020 May;182(5):1111-1119. doi: 10.1111/bjd.18482. Epub 2019 Nov 28. Br J Dermatol. 2020. PMID: 31487383 Free PMC article. Clinical Trial.

1. Harman KE, Brown D, Exton LS et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177:1170-201.
1. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.
1. Davidson JE, Fu Q, Rao S et al. Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. Lupus Sci Med 2018; 5:e000237.
1. NHS England. Clinical commissioning policy: rituximab for immunobullous disease. Available at: https://www.england.nhs.uk/wp-content/uploads/2018/07/Rituximab-for-immu... (last accessed 5 October 2019).
1. Chen DM, Odueyungbo A, Csinady E et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol 2020; https://doi.org/10.1111/bjd.18482. [Epub ahead of print]